Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well bevacizumab given together with combination chemotherapy works in treating patients with metastatic colorectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

NCT00467142

Colorectal Cancer

COMPLETED PHASE2

Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

NCT00423696

Colorectal Cancer

COMPLETED PHASE2

Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT00628810

Colorectal Cancer

COMPLETED PHASE2

Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab

NCT00720512

Colorectal Cancer

TERMINATED PHASE3

Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer

NCT00052559

Adenocarcinoma of the Rectum Stage II Rectal Cancer Stage III Rectal Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Evaluate the objective response (complete and partial) rate in patients with metastatic colorectal adenocarcinoma treated with bevacizumab and modified FOLFIRI 3 chemotherapy.

Secondary

* Determine progression-free and overall survival.
* Determine the tolerance to this regimen.
* Evaluate the resectability rate.
* Evaluate biological markers predictive of the efficacy of this regimen.

OUTLINE: This is a multicenter study.

Patients receive bevacizumab IV over 30-90 minutes on day 1, irinotecan hydrochloride IV over 90 minutes on days 1 and 3, and fluorouracil IV continuously over 46 hours on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.

At 14 days after completing chemotherapy, patients with progressive or stable disease receive maintenance therapy comprising bevacizumab and capecitabine.

Biological specimens are collected at baseline and before the fourth course of chemotherapy.

After completion of study therapy, patients are followed every 3 months for 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bevacizumab

Intervention Type BIOLOGICAL

capecitabine

Intervention Type DRUG

fluorouracil

Intervention Type DRUG

irinotecan hydrochloride

Intervention Type DRUG

diagnostic laboratory biomarker analysis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* WHO performance status 0-1
* Life expectancy \> 12 weeks
* Absolute neutrophil count ≥ 1,000/mm³
* Platelet count ≥ 100,000/mm³
* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* Transaminases ≤ 2 times ULN (5 times ULN if liver metastases present)
* Alkaline phosphatase ≤ 2 times ULN (5 times ULN if liver metastases present)
* Creatinine ≤ 130 μmol/L OR creatinine clearance ≥ 30 mL/min
* Proteinuria \< 2+ or urine protein ≤ 1 g/24 hours
* Not pregnant or nursing
* Fertile patients of must use effective contraception

* See Disease Characteristics

Exclusion Criteria

* Uncontrolled cardiac disease
* Prior cerebral vascular accident
* Uncontrolled arterial hypertension
* Severe renal or hepatic insufficiency
* Prior arteriopathy
* Bleeding disorder or nonhealing wound
* Coagulopathy
* Other malignancy within the past 2 years except basal cell or squamous cell skin cancer or curatively treated carcinoma of the cervix
* Psychiatric disorder compromising comprehension or participation in the study
* Intestinal occlusion or subocclusion not caused by medical therapy

PRIOR CONCURRENT THERAPY:

* Prior adjuvant bevacizumab or irinotecan hydrochloride
* Concurrent aspirin (\> 325 mg/day) or therapeutic anticoagulants
* Surgery in the past 28 days

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No